サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1782941

ナルトレキソンとブプレノルフィンの世界市場

Naltrexone and Buprenorphine

出版日
ページ情報
英文 364 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.67円
ナルトレキソンとブプレノルフィンの世界市場
出版日: 2025年08月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 364 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ナルトレキソンとブプレノルフィンの世界市場は2030年までに77億米ドルに達する

2024年に38億米ドルと推定されるナルトレキソンとブプレノルフィンの世界市場は、2024～2030年の分析期間においてCAGR 12.3%で成長し、2030年には77億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるブプレノルフィンは、CAGR13.7%を記録し、分析期間終了時には55億米ドルに達すると予想されます。ナルトレキソン（Naltrexone）分野の成長率は、分析期間中CAGR 9.3％と推定されます。

米国市場は10億米ドルと推定、中国はCAGR16.8％で成長予測

米国のナルトレキソンとブプレノルフィン市場は2024年に10億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.8％と11.0％と予測されています。欧州では、ドイツがCAGR約9.8%で成長すると予測されています。

世界のナルトレキソンとブプレノルフィン市場- 主要動向と促進要因のまとめ

ナルトレキソンとブプレノルフィンはオピオイド中毒治療をどう変革するか？

ナルトレキソンとブプレノルフィンは、オピオイド中毒との戦いにおいて重要な薬として登場し、長期的な回復と再発予防のための効果的なソリューションを提供しています。ブプレノルフィンはオピオイドの部分作動薬であり、欲求と離脱症状を軽減します。一方、ナルトレキソンはオピオイド拮抗薬であり、オピオイドの作用を完全に遮断します。オピオイド使用障害（OUD）の世界の蔓延は、薬物補助療法（MAT）の需要の急増につながり、ナルトレキソンとブプレノルフィンは現代の依存症回復プログラムの骨格を形成しています。ブプレノルフィンの月1回注射やナルトレキソンのインプラントなどの徐放性製剤の開発により、毎日の服薬スケジュールに悩む患者の服薬アドヒアランス率はさらに向上しています。さらに、個別化医療の進歩により、より的を絞った治療アプローチが行われるようになり、患者固有の依存症プロファイルや病歴に基づいて最適な薬物療法が受けられるようになっています。

なぜヘルスケアシステム全体でこれらの薬剤の需要が高まっているのか？

オピオイド中毒の負担が増加していることから、世界中の政府やヘルスケア機関がMATプログラムへのアクセスを拡大し、ナルトレキソンとブプレノルフィンの需要が高まっています。特にオピオイド依存率の高い地域では、公衆衛生上の取り組みや有害物質削減戦略にこれらの薬剤が組み込まれたことで、治療の利用可能性が大幅に改善しました。さらに、規制当局の支援と処方ガイドラインの改訂により、プライマリ・ケア医がこれらの薬を処方することが容易になり、専門的な中毒治療センターの必要性がなくなりました。遠隔医療もまた、アクセス拡大に重要な役割を果たしています。バーチャル診察により、患者は地理的・物流的な障壁を乗り越えて、遠隔地から処方やフォローアップ・ケアを受けることができるからです。保険適用や償還プログラムにナルトレキソンとブプレノルフィンが組み込まれたことで、患者の経済的な負担や治療の継続性がさらに向上しました。

治療プロトコルの進化と技術革新は市場をどのように形成しているか？

依存症医学における継続的な調査は、ナルトレキソンとブプレノルフィンの有効性と安全性を高める革新的な治療アプローチにつながっています。ブプレノルフィン-ノロキソン製剤のような併用療法の導入は、治療効果を維持しながら誤用のリスクを低減しています。さらに、長時間作用型のインプラントやデポ注射の開発により、毎日の投与が不要になり、患者のコンプライアンスが向上することで、オピオイド中毒治療に革命が起きています。服薬アドヒアランスを追跡するモバイルアプリやバーチャルカウンセリングセッションなどのデジタルヘルスソリューションは、回復努力をさらに支援し、再発率を低下させています。オピオイド中毒治療に対する社会の認識が高まるにつれ、MATを取り巻く偏見は徐々に薄れ、より多くの患者が助けを求めるようになっています。

ナルトレキソンとブプレノルフィン市場に影響を与える主な成長促進要因は何か？

ナルトレキソンとブプレノルフィン市場の成長は、オピオイドの蔓延、MAT採用の増加、医薬品製剤の進歩など、いくつかの要因によってもたらされます。主な促進要因のひとつは、エビデンスに基づく治療アプローチが重視されるようになっていることであり、ヘルスケアプロバイダーは、オピオイド依存の管理に有効性が証明されている薬剤を優先的に使用しています。政府の取り組みやオピオイド危機介入プログラムへの資金援助も、こうした薬へのアクセス拡大に重要な役割を果たしています。遠隔医療やデジタルヘルスプラットフォームの出現は、患者の関与をさらに促進し、場所に関係なく治療を受けることを容易にしています。さらに、新たな製剤や送達方法を模索する進行中の臨床試験が今後の市場成長を牽引し、オピオイド中毒治療がアクセスしやすく、効果的で、患者中心の治療であり続けることが期待されています。

セグメント

製品タイプ（ブプレノルフィン、ナルトレキソン）、投与経路（経口投与、注射剤投与、埋め込み型投与）、流通チャネル（病院薬局、小売薬局、その他の流通チャネル）

調査対象企業の例

  • Actavis（now part of Teva Pharmaceuticals）
  • Alkermes plc
  • Alvogen
  • Amneal Pharmaceuticals, Inc.
  • Avet Pharmaceuticals Inc.
  • Braeburn Inc.
  • Dr. Reddy's Laboratories
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Johnson Matthey
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Mylan N.V.（now part of Viatris）
  • Orexo AB
  • Purdue Pharma L.P.
  • Rhodes Pharmaceuticals L.P.
  • Siegfried Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Titan Pharmaceuticals, Inc.
  • Veranova

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32278

Global Naltrexone and Buprenorphine Market to Reach US$7.7 Billion by 2030

The global market for Naltrexone and Buprenorphine estimated at US$3.8 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. Buprenorphine, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$5.5 Billion by the end of the analysis period. Growth in the Naltrexone segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 16.8% CAGR

The Naltrexone and Buprenorphine market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 16.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.8% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.

Global Naltrexone and Buprenorphine Market - Key Trends & Drivers Summarized

How Are Naltrexone and Buprenorphine Transforming Opioid Addiction Treatment?

Naltrexone and buprenorphine have emerged as critical medications in the fight against opioid addiction, offering effective solutions for long-term recovery and relapse prevention. These drugs function differently-buprenorphine is a partial opioid agonist that reduces cravings and withdrawal symptoms, while naltrexone is an opioid antagonist that blocks the effects of opioids altogether. The increasing prevalence of opioid use disorder (OUD) worldwide has led to a surge in demand for medication-assisted treatment (MAT), with naltrexone and buprenorphine forming the backbone of modern addiction recovery programs. The development of extended-release formulations, such as monthly buprenorphine injections and naltrexone implants, has further improved adherence rates among patients who struggle with daily medication schedules. Additionally, advancements in personalized medicine are leading to more targeted treatment approaches, ensuring that patients receive the most suitable medication based on their specific addiction profile and medical history.

Why Is There a Growing Demand for These Medications Across Healthcare Systems?

The rising burden of opioid addiction has prompted governments and healthcare organizations worldwide to expand access to MAT programs, increasing the demand for naltrexone and buprenorphine. The integration of these medications into public health initiatives and harm reduction strategies has significantly improved treatment availability, especially in regions with high opioid dependency rates. Additionally, regulatory support and revised prescription guidelines have made it easier for primary care physicians to prescribe these medications, eliminating the need for specialized addiction treatment centers. Telemedicine has also played a crucial role in expanding access, as virtual consultations enable patients to receive prescriptions and follow-up care remotely, overcoming geographical and logistical barriers. The inclusion of naltrexone and buprenorphine in insurance coverage and reimbursement programs has further boosted patient affordability and adherence to treatment.

How Are Evolving Treatment Protocols and Innovation Shaping the Market?

Ongoing research in addiction medicine is leading to innovative treatment approaches that enhance the effectiveness and safety of naltrexone and buprenorphine. The introduction of combination therapies, such as buprenorphine-naloxone formulations, has reduced the risk of misuse while maintaining therapeutic efficacy. Additionally, the development of long-acting implants and depot injections has revolutionized opioid addiction treatment by eliminating the need for daily dosing and improving patient compliance. Digital health solutions, such as mobile apps for medication adherence tracking and virtual counseling sessions, are further supporting recovery efforts and reducing relapse rates. As public awareness of opioid addiction treatment increases, the stigma surrounding MAT is gradually diminishing, encouraging more individuals to seek help.

What Are the Key Growth Drivers Influencing the Naltrexone and Buprenorphine Market?

The growth in the naltrexone and buprenorphine market is driven by several factors, including the rising opioid epidemic, increasing adoption of MAT, and advancements in pharmaceutical formulations. One of the primary drivers is the growing emphasis on evidence-based treatment approaches, with healthcare providers prioritizing medications that offer proven efficacy in managing opioid dependency. Government initiatives and funding for opioid crisis intervention programs have also played a crucial role in expanding access to these medications. The emergence of telemedicine and digital health platforms has further facilitated patient engagement, making it easier for individuals to receive treatment regardless of location. Additionally, ongoing clinical trials exploring novel formulations and delivery methods are expected to drive future market growth, ensuring that opioid addiction treatment remains accessible, effective, and patient-centered.

SCOPE OF STUDY:

The report analyzes the Naltrexone and Buprenorphine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Buprenorphine, Naltrexone); Administration Route (Oral Administration, Injectable Administration, Implantable Administration); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Actavis (now part of Teva Pharmaceuticals)
  • Alkermes plc
  • Alvogen
  • Amneal Pharmaceuticals, Inc.
  • Avet Pharmaceuticals Inc.
  • Braeburn Inc.
  • Dr. Reddy's Laboratories
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Johnson Matthey
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Mylan N.V. (now part of Viatris)
  • Orexo AB
  • Purdue Pharma L.P.
  • Rhodes Pharmaceuticals L.P.
  • Siegfried Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Titan Pharmaceuticals, Inc.
  • Veranova

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Naltrexone and Buprenorphine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Opioid Use Disorder Expands Demand for Naltrexone and Buprenorphine Therapies
    • Shift Toward Medication-Assisted Treatment (MAT) Models Strengthens Adoption in Recovery Programs
    • Regulatory Support for Expanded Access to MAT Drugs Drives Prescriber Uptake and Reimbursement
    • Increased Inclusion of Buprenorphine in National Treatment Guidelines Sustains Prescription Growth
    • Clinical Evidence Supporting Safety and Efficacy of Combined Therapies Enhances Provider Confidence
    • Technological Advancements in Long-Acting Depot Formulations Improve Patient Compliance
    • Surge in Virtual Behavioral Health Platforms Fuels Telehealth Prescriptions of MAT Medications
    • Government Subsidies and Public Health Initiatives Propel Treatment Availability in Underserved Regions
    • Stigma Reduction Campaigns and Public Education Efforts Throw the Spotlight on Naltrexone Use
    • Rising Integration of Digital Therapeutics with MAT Supports Holistic Recovery Models
    • Growing Availability of Community-Based MAT Services Strengthens Local Market Penetration
    • Revised DEA Guidelines and Scope-of-Practice Flexibility Expand Access Through Primary Care Channels
    • Advancements in Subdermal and Transdermal Delivery Systems Drive Convenience-Driven Demand
    • Policy Focus on Reducing Relapse Rates and Overdose Deaths Propels Sustained Market Growth
    • Support for Medication-First Harm Reduction Models Accelerates Adoption in Urban and Rural Clinics
    • Globalization of MAT Protocols Opens Cross-Border Opportunities for Drug Manufacturers
    • Pharmacy Dispensing of Buprenorphine Tablets Supports Non-Specialist Engagement and Access
    • Collaborative Care Models and Integrated Recovery Pathways Strengthen Adherence Outcomes
    • Pricing Reforms and Generic Competition Drive Affordability in Long-Term Therapy Scenarios
    • Increased R&D in Novel Opioid Receptor Modulators Spurs Pipeline Activity for Next-Gen MAT Agents
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Naltrexone and Buprenorphine Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Naltrexone and Buprenorphine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Naltrexone and Buprenorphine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Buprenorphine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Buprenorphine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Buprenorphine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Naltrexone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Naltrexone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Naltrexone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Implantable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Implantable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Implantable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Naltrexone and Buprenorphine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Naltrexone and Buprenorphine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Naltrexone and Buprenorphine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Naltrexone and Buprenorphine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Naltrexone and Buprenorphine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Naltrexone and Buprenorphine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Naltrexone and Buprenorphine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Naltrexone and Buprenorphine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Naltrexone and Buprenorphine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Naltrexone and Buprenorphine by Product Type - Buprenorphine and Naltrexone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Naltrexone and Buprenorphine by Product Type - Percentage Breakdown of Value Sales for Buprenorphine and Naltrexone for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Naltrexone and Buprenorphine by Administration Route - Oral Administration, Injectable Administration and Implantable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Naltrexone and Buprenorphine by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Implantable Administration for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Naltrexone and Buprenorphine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Naltrexone and Buprenorphine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION